Search
Repinotan
go.drugbank.com/drugs/DB06506InvestigationalRepinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Marimastat
go.drugbank.com/drugs/DB00786InvestigationalUsed in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from brea...
CR665
go.drugbank.com/drugs/DB05155ExperimentalCR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists. In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal...
Ranirestat
go.drugbank.com/drugs/DB05327InvestigationalRanirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studyi...
CRx-119
go.drugbank.com/drugs/DB05688ExperimentalCRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of immuno-inflammatory conditions. CRx...
VT-111
go.drugbank.com/drugs/DB05646InvestigationalVT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.
Linsitinib
go.drugbank.com/drugs/DB06075InvestigationalAn orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tum...
XP21279
go.drugbank.com/drugs/DB06319InvestigationalXP21279 is a prodrug of Levodopa, a dopamine precursor used in the management of Parkinson's disease. XP21279 was under investigation in clinical trial NCT00914602 (An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinso...
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...